SPICE trial: enadenotucirev with nivolumab in tumors of epithelial origin
Marwan Fakih, MD, City of Hope Comprehensive Cancer Center, Duarte, CA, talks about the rationale behind the SPICE study (NCT02636036)…
Related Articles
Biomarkers to guide MDR and hormonal treatment choice in prostate cancer
Eric Bent, MD, PhD, Memorial Sloan-Kettering Cancer Center, Cambridge, MA, illuminates the future use of biomarkers that promise an enhanced, more precise prostate cancer treatment…
TRUST: optimal timing of surgical therapy in advanced ovarian cancer
Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, discusses the TRUST study (NCT02828618), a prospective randomized trial on the timing of surgery in advanced…
Breakthrough advances from ESMO GI 2025
This week’s VJOncology podcast episode highlights four breakthrough studies from ESMO GI 2025 in Barcelona, Spain, featuring expert insights on…
Evaluating bevacizumab with pembrolizumab & chemotherapy in cervical cancer
Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)
What are the barriers to ctDNA monitoring in endometrial cancer?
Shannon Westin, MD, FASCO, The University of Texas MD Anderson Cancer Center, and GOG-F, Houston, TX, discusses the current limitations facing the integration of circulating…
STARLITE-1: 177Lu-girentuximab, cabozantinib & nivolumab in ccRCC
Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the Phase Ib/II STARLITE-1 trial (NCT05533242) of 177Lu-girentuximab with cabozantinib and…
Phase I/IIa trial of IVS-3001, a HLA-G-targeting CAR-T therapy, in solid tumors
Samer Srour, MB ChB, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on an ongoing Phase I/IIa trial (NCT05672459) investigating IVS-3001,…
Phase III trial of rinatabart sesutecan in platinum-resistant ovarian cancer
Angeles Secord, MD, Duke Cancer Institute, Durham, NC, gives an overview of the Phase III RAINFOL-02 trial (NCT06619236) evaluating rinatabart sesutecan (Rina-S) versus investigator’s choice…
Clinical implementation of ctDNA monitoring for NSCLC
Aslaug Helland, MD, PhD, University of Oslo, Oslo, Norway, emphasizes the need for standardization in studies on circulating tumor cells (CTCs) and cell-free DNA (cfDNA)…
Tissue-selective estrogen complexes as a new treatment for DCIS
Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, comments on the significance of the PROMISE study (NCT02694809) of conjugated estrogen/bazedoxifene (CE/BZA) for…